The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRDL | -36.76% | -48.46% | -12.41% | -69% |
| S&P | +16.23% | +94.45% | +14.22% | +158% |
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | 59.3% |
| Market Cap | $112.40M | -19.4% |
| Market Cap / Employee | $5.11M | 0.0% |
| Employees | 22 | 0.0% |
| Net Income | -$6.04M | -25.3% |
| EBITDA | -$5.53M | 1.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $13.33M | -24.0% |
| Accounts Receivable | $0.04M | -36.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.08M | -24.7% |
| Short Term Debt | $0.03M | 64.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -159.53% | -80.6% |
| Return On Invested Capital | -100.33% | -12.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.48M | -1.7% |
| Operating Free Cash Flow | -$3.47M | -1.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 12.23 | 11.64 | 4.66 | 9.19 | -1.20% |
| Price to Tangible Book Value | 12.36 | 11.64 | 4.66 | 9.19 | -2.13% |
| Enterprise Value to EBITDA | -12.47 | -11.82 | -10.68 | -17.88 | -16.20% |
| Return on Equity | -158.5% | -138.8% | -190.6% | -271.6% | 154.04% |
| Total Debt | $0.12M | $0.11M | $0.10M | $0.10M | -12.98% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
